Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Offers $4,000 To Cover Cost Of Third-Party Review Expenses

This article was originally published in The Gray Sheet

Executive Summary

FDA would provide the first $4,000 to help companies defray the cost of third-party 510(k) review for eligible devices, the agency explains in its FY 2001 budget justification document.

You may also be interested in...



MeDSuN Pilot Funding Included In Budget; Program To Begin In Six Months

Funded at $1.7 mil. in FDA's FY 2001 budget, the Medical Device Surveillance Network (MeDSuN) reporting system pilot is expected to become operational within six months, according to Center for Devices and Radiological Health Office of Surveillance and Biometrics Deputy Director Susan Gardner.

MeDSuN Pilot Funding Included In Budget; Program To Begin In Six Months

Funded at $1.7 mil. in FDA's FY 2001 budget, the Medical Device Surveillance Network (MeDSuN) reporting system pilot is expected to become operational within six months, according to Center for Devices and Radiological Health Office of Surveillance and Biometrics Deputy Director Susan Gardner.

Industry Meeting With HCFA Aimed At Amending "Final" OPPS List By July 1

The device industry is hopeful that a meeting with Health Care Financing Administration officials - scheduled to have occurred May 19 - will result in the addition by July 1 of more devices to the agency's final list of new technology eligible for added reimbursement under the outpatient prospective payment system.

Related Content

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel